Tracked deals
5
5 tracked deals across 2024-2025.
Greenwich, Connecticut, United States
3 Boomerang Capital is a private equity firm focused on lower middle market healthcare companies. The firm partners with entrepreneurs and management teams to drive accelerated growth and scale through organic growth and acquisitions.
Tracked deals
5
5 tracked deals across 2024-2025.
Recent pace
1
1 tracked deal announced in the last 12 months.
Deal mix
Addon
3 addon · 1 growth capital · 1 recapitalization
Last 2 years
Supporting Data
Enjoin, a 3 Boomerang Capital portfolio company, has acquired Pediatric Resource Group (PRG), a pediatric-focused clinical documentation integrity (CDI) and physician advisory firm. The add-on expands Enjoin’s DRG assurance and revenue integrity capabilities to include pediatric and neonatal APR-DRG expertise for children’s hospitals and health systems nationwide.
Pinnaql, a LSOMS/3 Boomerang Capital portfolio company, has acquired Validation & Engineering Group, Inc. (VEG), a provider of commissioning, qualification, and validation (CQV) services to the pharmaceutical and life sciences industries. The add-on expands Pinnaql’s CQV and engineering capabilities and geographic footprint as part of its broader life‑sciences compliance and quality services platform.
LSOMS Holdings, a platform backed by 3 Boomerang Capital, acquired Pinnaql, a provider of laboratory validation and global GxP compliance services. The majority investment is LSOMS's first acquisition and expands the platform's quality, regulatory, and lab validation capabilities for pharmaceutical, biotech, and medical device clients.
3 Boomerang Capital has made a strategic growth investment in Bio-Response Solutions to provide capital and resources to accelerate the company’s expansion in regulated biomedical waste management. The investment will support scaling operations and expanding Bio-Response’s Aquamation and scientific sterilization equipment into funeral homes, veterinary clinics, and high-containment laboratory end markets.
3 Boomerang Capital completed a majority growth recapitalization of Enjoin, LLC, a Clinical Documentation Integrity (CDI) and mid-revenue cycle solutions provider for hospitals and health systems. The investment will supply strategic resources and capital to expand Enjoin's tech-enabled CDI capabilities and support continued growth across healthcare provider markets.
Turn tracked acquisition activity into an outreach-ready buyer list.